- Neuroendocrine Cancer
- Newly Diagnosed
- Carcinoid & Neuroendocrine Tumor Patient Community
- Doctor Database
- Clinical Trials
- Educational Resources
- Additional Resources
- Join Us For a Cure
- Researching Funding Opportunities
- Current Research Grants
- Previous Research Grants
- Research Approach
- Board of Scientific Advisors
- Research Results
- About Us
- CFCF News
- Founder Nancy Lindholm
- Corporate Sponsorship
Neuroendocrine Tumor Biomarkers
Action #4: Discover New Carcinoid Biomarkers
Fundraising Target: $250,000
There are no carcinoid biomarkers to accurately predict when carcinoid will occur, prognosticate its course, and measure its endpoints. As a result, carcinoid diagnosis comes too late, treatments are not individualized, and outcomes are not accurately measured.
The National Cancer Institute (NCI) asserts that biomarkers are critical to cutting-edge cancer research. The NCI symposium, "Clinical Proteomics and Biomarker Discovery in Cancer Research", stated:
"An effective platform for clinical biomarker discovery would revolutionize clinical oncology. Such a platform would enable detection of disease early, when it is curable. It would also provide a means of distinguishing quickly those patients who are responding to a given therapy from those who are not, as well as yielding perhaps the ultimate preventive tool capable of identifying those at risk for cancer and even predicting their response to prevention interventions."
It is urgent to discover new carcinoid biomarkers to achieve this revolution in the diagnosis, treatment, and prevention of carcinoid.
Our objective is to discover new carcinoid biomarkers:
- To predict when carcinoid will occur
- To prognosticate the course of each carcinoid patient
- To measure the endpoints of carcinoid
If we achieve our fundraising target of $250,000, we will issue a Research RFP to discover new carcinoid biomarkers.